JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth
Authors:
- 30 August 2011
- journal article
- research article
- Published by Taylor & Francis in Growth Factors
- Vol. 29 (6) , 245-252
Abstract
The four Janus kinases (JAKs) comprise a family of intracellular, nonreceptor tyrosine kinases that first gained attention as signaling mediators of the type I and type II cytokine receptors. Subsequently, the JAKs were found to be involved in signaling downstream of the insulin receptor, a number of receptor tyrosine kinases, and certain G-protein coupled receptors. Although a number of cytoplasmic targets for the JAKs have been identified, their predominant action was found to be the phosphorylation and activation of the signal transducers and activators of transcription (STAT) factors. Through the STATs, the JAKs activate gene expression linked to cellular stress, proliferation, and differentiation. The JAKs are especially important in hematopoiesis, inflammation, and immunity, and aberrant JAK activity has been implicated in a number of disorders including rheumatoid arthritis, psoriasis, polycythemia vera, and myeloproliferative diseases. Although once thought to reside strictly in the cytoplasm, recent evidence shows that JAK1 and JAK2 are present in the nucleus of certain cells often under conditions associated with high rates of cell growth. Nuclear JAKs have now been shown to affect gene expression by activating other transcription factors besides the STATs and exerting epigenetic actions, for example, by phosphorylating histone H3. The latter action derepresses global gene expression and has been implicated in leukemogenesis. Nuclear JAKs may have a role as well in stem cell biology. Here we describe recent developments in understanding the noncanonical nuclear actions of JAK1 and JAK2.Keywords
This publication has 81 references indexed in Scilit:
- Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle controlOncogene, 2011
- LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell diseaseNature Cell Biology, 2010
- Prolactin-induced Jak2 phosphorylation of RUSH: A key element in Jak/RUSH signalingMolecular and Cellular Endocrinology, 2010
- Co‐administration of the JAK inhibitor CP‐690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentBritish Journal of Clinical Pharmacology, 2010
- JAK redux: a second look at the regulation and role of JAKs in the heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaJournal of Experimental Medicine, 2008
- Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesisProceedings of the National Academy of Sciences, 2007
- Mechanisms of specificity in protein phosphorylationNature Reviews Molecular Cell Biology, 2007
- JAK signaling globally counteracts heterochromatic gene silencingNature Genetics, 2006
- Nuclear Jak2 and Transcription Factor NF1-C2: a Novel Mechanism of Prolactin Signaling in Mammary Epithelial CellsMolecular and Cellular Biology, 2006